Screening recommendations, triple therapy and more—here are insights into the upcoming ACR guideline for the care and treatment of patients with lupus nephritis.
Vitamin D has gotten a lot of press over the years. But is it actually worth the hype, especially when it comes to autoimmunity? Does it prevent the onset of autoimmune disease? Does it have a role in treatment? Experts in this ACR Convergence 2024 session helped decipher the role of vitamin D in bone health, immune regulation and infection reduction.
Rheumatic diseases are intrinsically linked to environmental conditions. With a constantly changing environment, how can rheumatologists adapt to the challenges of global climate change, pollution and other environmental threats? The Environment + Genetics Tamiko Katsumoto, MD, a clinical associate professor in the Division of Immunology and Rheumatology at Stanford University, Palo Alto, Calif., emphasizes the…
Fava et al. investigated longitudinal autoantibody profiles in patients with lupus nephritis (LN) to define serological biomarkers of histologic class. They found that baseline levels of anti-C1q and anti-double-stranded DNA antibodies may serve as noninvasive biomarkers of proliferative LN and anti-C1q antibodies may predict complete response.
An understanding of the mechanisms underlying NET-mediated inflammation will empower clinicians to target therapies that can mitigate disease activity & improve outcomes in patients with lupus.
With more than 350 research abstracts on systemic lupus erythematosus, lupus nephritis and related conditions accepted for presentation at ACR Convergence 2024, we’re happy to announce that Graciela S. Alarcón, MD, MPH, has accepted the monumental task of reviewing the abstracts and identifying those most likely to make a difference to clinical practice or lead…